Biotechnology & Life Sciences

Claims where the contested frontier lies in whether evidence of efficacy, safety, and scale keeps pace with the deployment of biological interventions.

Recent Activity

2026-06-29FR-BT-0002OQ-004 added: what a single Phase 1 trial result would or would not satisfy of AT-001's two-part attractor condition.Escalating

2026-06-29FR-BT-0002IN-006 added: Life Biosciences ER-100 FDA IND clearance, first human partial-reprogramming trial, stated Q1 2026 start.Escalating

2026-06-27FR-BT-0004INST-006 added (NHS-Galleri full trial results, ASCO 2026).Fragmenting

Evidence Trajectories - PROG-BT

View Biotechnology & Life Sciences trajectoriesBT records are brought forward within the full archive.

Frontier Records — PROG-BT

FR-BT-0001Senolytic Therapies — Meaningful Human Healthspan ExtensionEscalating1 assessment2024-01-15 FR-BT-0002Epigenetic Reprogramming — Biological Age Reversal Without Identity LossEscalating2 assessments2024-01-15 FR-BT-0003Biological Age Biomarker Panels — Predictive Validity for Age-Related DeclineFragmenting1 assessment2024-01-15 FR-BT-0004Liquid Biopsy — Early Cancer Detection Before Conventional DiagnosisFragmenting2 assessments2024-01-15

No current programme-level diagnosis.